Anti-angiogenic effects of imatinib target smooth muscle cells but not endothelial cells
- 272 Downloads
Knowing that progesterone up-regulates PDGF-A, which plays a relevant role in angiogenesis, and that imatinib mesylate targets PDGF receptor tyrosine kinase activity, the aim of the present study was to examine the effects of imatinib on Human Aortic Smooth Muscle Cells (HAoSMC) and Human Umbilical Vein Endothelial Cells (HUVEC) after incubation with progesterone. Expression of phosphorylated (activated) PDGFR-α was detected in HAoSMC, but in a very low extent in HUVEC. In agreement with the lack of active PDGFR-α, imatinib was unable to prevent HUVEC growth, survival or migration ability. In contrast, HAoSMC viability and proliferation were effectively inhibited by imatinib, as evaluated by MTT and BrdU incorporation assay, respectively. Corroborating these findings, a significant increase in the percentage of apoptotic cells was also observed after treatment with imatinib. Cell migration assays also showed a reduction in the migratory ability after incubation with imatinib. Altogether, these facts reveal that imatinib is able to affect HAoSMC survival, growth and migration. Furthermore, incubation with recombinant PDGF as well as, with progesterone seems to sustain PDGFR-α activity, prompting these cells to the inhibitory action of imatinib. These findings were restricted to smooth muscle cells, leading to the assumption that imatinib is probably preventing vessel stabilization, a crucial event for neovascular maturation. Our findings indicate that imatinib might be a good therapeutic agent against atherosclerosis and other vascular-associated disorders that carry in common smooth muscle cells abnormal growth.
KeywordsAngiogenesis Apoptosis Cell growth Imatinib Migration PDGF Progesterone Tyrosine kinase
We would like to thank Novartis Pharma (Basel, Switzerland) for providing imatinib. The authors are grateful to Novartis Oncology (Portugal) and FCT (POCI, FEDER, Programa Comunitário de Apoio) for the financial support that enabled this study.
- 7.Chelouche D, Kim SJ, Onn A, Stone V, Nam DH, Yazici S, Fidler IJ, Price JE (2005) Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin Cancer Res 11:306–314Google Scholar
- 9.Edelberg JM, Lee SH, Kaur M, Tang L, Feirt NM, McCabe S, Bramwell O, Wong SC, Hong MK (2002) Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: feasibility of restoring impaired angiogenic capacity in the aging heart. Circulation 105(5):608–613PubMedCrossRefGoogle Scholar
- 17.Kim R, Emi M, Arihiro K, Tanabe K, Uchida Y, Toge T (2005) Chemosensitization by STI571 targeting the platelet-derived growth factor/Platelet-derived growth factor receptor-signaling pathway in the tumour progression and angiogenesis of gastric carcinoma. Cancer 103(9):1800–1809PubMedCrossRefGoogle Scholar
- 21.Machens HG, Morgan JR, Berthiaume F, Stefanovich P, Siemers F, Krapohl B, Berger A, Mailander P (2002) Platelet-derived growth factor-AA-mediated functional angiogenesis in the rat epigastric island flap after genetic modification of fibroblasts is ischemia dependent. Surgery 131(4):393–400PubMedCrossRefGoogle Scholar
- 29.Rocha A, Azevedo I, Soares R (2007) Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects. J Cell Biochem (in press) (ISSN: 1097-4644)Google Scholar
- 32.Taylor C (2000) Platelet-derived growth factor activates porcine thecal cell phosphatidylinositol-3-kinase-Akt/PKB and ras-extracellular signal-regulated kinase-1/2 kinase signaling pathways via the platelet-derived growth factor-beta receptor. Endocrinology 141:1545–1553PubMedCrossRefGoogle Scholar
- 33.Tsutsumi N, Yonemitsu Y, Shikada Y, Onimaru M, Tanii M, Okano S, Kaneko K, Hasegawa M, Hashizume M, Maehara Y, Sueishi K (2004) Essential role of PDGFRalpha-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo: role of PDGFRalpha during angiogenesis. Circ Res 94(9):1186–1194PubMedCrossRefGoogle Scholar